“He will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon.”
$RLFTF Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer Geneva, Switzerland, September 04, 2020
– RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company“), a biopharmaceutical company with its lead compound aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Gilles Della Corte, M.D., as Chief Medical Officer, effective immediately.
Dr. Della Corte held several senior clinical research positions at Merck Serono (previously Serono), where he was responsible for the development from proof of concept to life cycle management of projects in several disease areas, including cardiology, rheumatology, oncology and endocrinology.
Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
"He will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon.” Said the Chairman of the board
Market Data 
Markets 
AI
